Home » OSI Pharmaceuticals Receives Additional U.S. Patent for Tarceva
OSI Pharmaceuticals Receives Additional U.S. Patent for Tarceva
OSI Pharmaceuticals has been issued a U.S. patent covering the production process for a crystalline polymorph of its cancer drug Tarceva (erlotinib HCl).
The claims in the patent will extend exclusive protection of Tarceva until 2020, the company said. Tarceva is also protected by a U.S. patent issued in 1998 that covers composition of matter, preparation processes, methods of treating cancer and pharmaceutical compositions containing Tarceva.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct